Mergers and acquisitions have always been exercises in identifying, pricing and managing risk. For much of corporate history, that risk was understood primarily in financial, operational and regulatory terms balance sheet liabilities, workforce integration, antitrust clearance and market concentration. In the contemporary deal landscape and most acutely in India’s rapidly maturing M&A market, this understanding has undergone a structural transformation. Intellectual property and patents in particular have migrated from a peripheral item in the due diligence checklist to a primary value driver and, in many transactions, the central determinant of deal rationale itself. A company’s patent portfolio can account for the majority of its enterprise value, define the boundaries of its competitive moat, generate material licensing revenue, expose it to infringement liability and, in the Indian context, with its distinctive compulsory licensing framework, carry regulatory risks that have no equivalent in other jurisdictions.
Yet despite this transformation, IP due diligence in India remains, as practitioners and researchers have consistently observed, inconsistently practised. A study reported in the SSRN noted that approximately forty-six to sixty per cent of M&A transactions fail because of improper IP due diligence, a sobering statistic that reflects not the irrelevance of IP to deal outcomes but the persistent under investment in rigorous IP assessment at the pre-closing stage. The consequences of this under investment post-closing valuation write-downs, disputes over IP ownership, the discovery of undisclosed infringement claims and, in the most serious cases, the complete unravelling of the deal rationale are well-documented and increasingly expensive. Understanding why patent valuation and due diligence matter, how they should be conducted under the applicable Indian legal framework and what the landmark transactions of the Indian market teach us about the consequences of getting it right or wrong, is the task this article undertakes.
The Shifting Centre of Gravity – Why Patents Drive M&A Value
The shift in the centre of M&A value from tangible to intangible assets is a global phenomenon, but it has particular intensity in the sectors that dominate high-value Indian deal activity. In pharmaceuticals, where companies like Sun Pharma, Dr Reddy’s and Cipla have built global enterprises on patent-backed product portfolios, the value of a transaction is overwhelmingly a function of the acquired entity’s patent estate: the drugs it can exclusively manufacture and sell, the territories in which those exclusivity are enforceable, the remaining term on those patents and the pipeline of pending applications that will determine future competitive positioning. In technology, where India’s software and digital economy companies attract substantial domestic and cross-border investment, proprietary algorithms, software architectures and increasingly hardware patents define the value of the underlying business. In manufacturing and engineering, where global corporations acquire Indian operations for their process innovations and technology capabilities, the ability to identify, verify and correctly value the relevant patents is a prerequisite to rational deal pricing.
The proportion of enterprise value attributable to intangible assets of which patents are typically the most legally defined and verifiable, has grown consistently across all major sectors. An acquirer who prices a pharmaceutical company based on its revenue multiples without independently assessing the patent expiry dates of its leading products, the validity of the patents underlying its pipeline and the compulsory licensing exposure of its high-value drugs has not conducted a commercially defensible transaction. An investor who values a technology startup based on its user growth without examining whether the algorithms that drive the platform are proprietary, adequately protected and owned by the company rather than by its founders or third-party developers, has left the most consequential risk entirely unassessed.
The Indian Legal Framework – Statutory Foundations for Patent Due Diligence
Patent due diligence in India must be grounded in the applicable statutory framework, which differs from that of other major M&A jurisdictions in ways that create both distinctive risks and distinctive opportunities. The Patents Act, 1970, as amended in 2005 and further updated by the Patents (Amendment) Rules, 2024, governs patent protection in India and contains several provisions of direct relevance to M&A due diligence.
Section 6 of the Act provides that a patent may be applied for by the true and first inventor or by their assignee. Section 68 requires that assignments of patents be in writing and registered with the Controller of Patents to be valid against third parties; an unregistered assignment is not effective against a third-party acquirer who takes a patent in good faith. This provision has direct M&A relevance: an acquirer who inherits a patent portfolio must verify not only that the target company appears in the patent register as the recorded proprietor but that any chain of assignment that led to that registration was properly documented and registered at each link. Gaps in the assignment chain, particularly those arising from unregistered transfers between predecessors in title or from the failure to record assignments following corporate restructurings, create title defects that can undermine the acquirer’s ability to enforce the patent post-closing.
Section 20(1) of the Act, which provides that employee inventors own the patents they create in the absence of a contract to the contrary, creates a specific and frequently underappreciated risk in the M&A context. A target company whose employment agreements do not contain clear and properly executed IP assignment clauses may not own the patents nominally in its name the intellectual and legal ownership may remain with the individual employees or former employees who made the underlying inventions. The Bombay High Court’s decision in Darius Rutton Kavasmaneck v. Gharda Chemicals Ltd. (2014) confirmed that employer ownership of employee inventions cannot be assumed from the employment relationship alone and must rest on a contractual foundation. The due diligence process must therefore examine not only the patent register but the employment agreements of the inventors named in each material patent, to verify that the chain of title from inventor to target company is legally sound.
Section 3(d) of the Act, the provision that disallows patents on new forms of known substances without demonstrably enhanced efficacy, affirmed by the Supreme Court in Novartis AG v. Union of India (2013), is among the most litigated provisions in pharmaceutical patent due diligence. An acquirer of a pharmaceutical company must assess each material patent against the Section 3(d) standard, identifying those whose validity might be challenged in post-grant opposition or revocation proceedings on this ground. A patent that satisfies the validity standard of the granting jurisdiction but falls foul of Section 3(d) in India may carry significantly less value in an Indian deal context than its face value on the patent register suggests.
Sections 84 and 92, the compulsory licensing provisions, introduce a risk category that is unique to the Indian jurisdiction. A patent estate that appears legally robust and commercially valuable in every conventional sense may nonetheless carry material compulsory licensing exposure if its products are priced at levels that Indian regulatory and judicial authorities might characterize as not reasonably affordable or if the patented technology is not being adequately worked with in India. As the landmark decision in Bayer Corporation v. Natco Pharma Ltd. (2012) demonstrated, India’s first compulsory licence was granted over a product patent that Bayer unquestionably held, and that was entirely valid; the vulnerability arose not from any defect in the patent but from the commercial and public interest circumstances surrounding its exploitation. Any acquirer of an Indian pharmaceutical company holding product patents or any foreign acquirer of a company with patents that cover essential technologies must conduct a specific compulsory licensing risk assessment as a component of patent due diligence, examining pricing, public availability and the geographic distribution of manufacturing activity.
Patent Valuation – The Three Principal Approaches
Alongside the legal assessment of patent validity, ownership and enforceability, the M&A due diligence process requires a commercial valuation of the patent portfolio and an estimate of the economic value the patents are expected to deliver to the acquiring entity. Patent valuation in India does not follow a single prescribed statutory or regulatory methodology. Instead, it is approached through three established frameworks, each of which offers a different perspective on value and in practice a combination of these approaches is typically employed.
The income approach values a patent by reference to the future economic benefits it is expected to generate: the discounted present value of the royalty income, licensing revenue or incremental profits attributable to the patent’s exclusivity over its remaining term. This approach requires projections of future revenue, estimates of the portion of that revenue attributable to the patent as distinct from other competitive factors, selection of an appropriate royalty rate (often bench-marked against comparable licence transactions) and application of a discount rate reflecting the risk of the projected income stream. The income approach is the most intellectually direct method for capturing the commercial value of a patent as an income-generating asset, and it is the preferred approach where reliable licensing or revenue data is available. Its weaknesses are its dependence on forecasting assumptions that may be highly uncertain and its sensitivity to the choice of discount rate, which can produce dramatically different valuations from the same underlying revenue projections.
The market approach values a patent by reference to the prices paid in comparable transactions licensing agreements, patent sales or M&A deals involving similar patents in similar technical fields. This approach is conceptually appealing because it grounds the valuation in actual market evidence rather than projected cash flows, but it is practically challenging in the patent context because genuinely comparable transactions are often confidential and even disclosed transaction prices may reflect deal-specific factors that make direct comparison unreliable. In India, where the patent licensing and patent sale markets are less developed than in the United States or Europe, comparable data is particularly limited, and the market approach functions more as a cross-check than a primary valuation method.
The cost approach values a patent by reference to the cost that would be required to reproduce or replace it, the historical R&D expenditure that produced the invention, or the hypothetical cost of developing a commercially equivalent technology through an alternative route. The cost approach is most useful where the patent represents a discrete technical solution and where R&D costs are well-documented. It tends to undervalue patents whose commercial utility substantially exceeds their development cost, which is common with genuinely innovative inventions, and it does not capture the market exclusivity premium that is a central feature of patent value. As a standalone method it is generally inadequate for high-value patent portfolios in M&A transactions, but it provides a useful floor valuation and a check on the reasonableness of income or market-based estimates.
Beyond these three core approaches, additional analytical tools enrich the patent valuation exercise in the M&A context. Citation analysis examining the degree to which a patent is cited by subsequent patents, by competitors and in litigation provides an indicator of the patent’s technological significance and commercial relevance. Patent strength assessment examines the breadth of the claims, the quality of the prosecution history, the likelihood of surviving validity challenges and the remaining term. Freedom-to-operate analysis assesses whether the target’s commercial activities infringe third-party patents a question of equal importance to the valuation of the target’s own portfolio, since undisclosed freedom-to-operate problems can materially impair the value of an otherwise attractive business.
The Due Diligence Process – Structure and Methodology
Patent due diligence in an M&A context is a structured, multi-phase process that must be carefully planned, resourced with the right expertise and executed with a clear understanding of its purpose to identify, quantify and, where possible, remediate IP risks before the transaction closes and to provide the deal team with the information it needs to price those risks correctly.
The first phase is identification and inventory. The due diligence team must compile a comprehensive schedule of all patents and patent applications owned by, licensed to or otherwise relevant to the target company, across all relevant jurisdictions. This requires searches of the Indian Patent Office register, national patent office databases in all jurisdictions where the target has material commercial activity, and the patent family databases maintained by the European Patent Office and WIPO. The inventory must capture not only granted patents but pending applications, lapsed patents that might be capable of restoration and patents in which the target holds an interest as licensee rather than proprietor. In India, the Indian Patent Office’s public search facility and the InPASS database provide the primary tools for domestic searching, though these databases have historically suffered from data quality and completeness issues that make independent searching by reference to inventor names and technical classifications a necessary supplement.
The second phase is title and ownership verification. For each material patent, the due diligence team must trace the chain of title from the named inventor or inventors to the target company, verifying that each assignment or transfer in the chain was properly documented and registered. As noted above, Section 68 of the Patents Act requires registration of assignments for validity against third parties and gaps in the registered chain are title defects that must be remediated ideally before closing through the execution and registration of corrective assignment documents. The employment agreements of named inventors, particularly those relating to inventions made before formal employment agreements were standardized, require careful scrutiny. Where the target company has a history of acquiring technology through external collaborations, sponsored research agreements or government funding, the due diligence team must examine each of those arrangements to confirm that the target’s ownership of the resulting IP was properly documented at the time.
The third phase is validity and enforceability assessment. Not all granted patents are created equal. A patent that has survived a post-grant opposition proceeding carries greater presumption of validity than one that has never been challenged. Patents approaching expiry may have limited value relative to younger applications in the same portfolio. Patents whose claims were significantly narrowed during prosecution may protect less than their face reading suggests. In the pharmaceutical context, a Section 3(d) vulnerability assessment is an essential component of validity analysis. The due diligence team which must include patent practitioners with relevant technical expertise, not merely legal generalists, should form a view on the vulnerability of each material patent to invalidity challenge and the likely commercial consequences of successful invalidation.
The fourth phase is freedom-to-operate analysis. An acquiring company needs to understand not only what IP the target owns but whether the target’s commercial operations are at risk from third-party patent enforcement. Freedom-to-operate searches identify patents held by third parties that may cover the target’s products or processes, assess the likelihood and commercial materiality of enforcement risk and inform the deal team’s understanding of the competitive landscape the acquirer will inherit. In technology-intensive sectors, freedom-to-operate analysis can reveal that a business operating successfully in its market nonetheless faces material patent exposure that has not been reflected in its commercial performance simply because no enforcement action has yet been brought. The acquirer inherits that exposure at closing.
The fifth phase is licensing and contractual review. Patents do not exist in isolation they are typically embedded in a web of licence agreements, research collaboration agreements, co-ownership arrangements and encumbrances that define the practical scope of the rights the acquirer will obtain. Material licence agreements must be reviewed for change-of-control provisions: a licence that terminates automatically upon a change of control of the licensor or licensee can eliminate a critical technology right post-closing without any formal act of the parties. Sub-licence rights whether the target has granted sub-licences and whether those sub-licences are consistent with the terms of the head licence must be verified. Co-ownership arrangements under Indian patent law are particularly significant: unlike some jurisdictions, Indian patent law permits a co-owner to independently work the patent without the consent of the other co-owner, which means that a patent nominally co-owned by the target and a third party may provide far less exclusivity than it appears.
Transaction Case Studies – What Indian M&A Teaches Us
The practical importance of rigorous patent due diligence in Indian M&A is illustrated with particular clarity by several landmark transactions, each of which reveals a different dimension of IP risk.
The Sun Pharma – Ranbaxy merger of 2014, which created India’s largest and the world’s fifth-largest generic pharmaceutical company, was a transaction in which IP risk was both the strategic rationale and the principal source of complication. Sun Pharma’s acquisition of Ranbaxy from Japan’s Daiichi Sankyo was driven in significant part by the opportunity to acquire Ranbaxy’s extensive product patent portfolio, its US abbreviated new drug application pipeline and its global manufacturing footprint. However, Ranbaxy carried substantial regulatory liabilities including a consent decree with the United States Food and Drug Administration arising from manufacturing and data integrity issues that materially impaired the value of its US-facing patent and product pipeline. The Competition Commission of India conducted a detailed Phase II investigation the first in its history, and ultimately ordered Sun Pharma and Ranbaxy to divest seven brands as a condition of merger clearance, appointing PricewaterhouseCoopers to supervise the divestment process. The transaction illustrates that in pharmaceutical M&A, the value of a patent portfolio is inseparable from the regulatory status of the manufacturing facilities through which it is exploited; a patent that cannot be manufactured compliantly generates no commercial value, regardless of its legal strength.
The Walmart–Flipkart acquisition of 2018, in which Walmart acquired a 77 per cent stake in Flipkart for USD 16 billion, making it the largest e-commerce acquisition in Indian history, presented a different IP due diligence profile. The commercial value of the transaction was anchored substantially in Flipkart’s brand, user base, proprietary technology platform and logistics infrastructure rather than in formal patent holdings. The Share Issuance and Acquisition Agreement, which is publicly available through SEC filings, required Flipkart to provide a detailed IP disclosure schedule identifying all patents, trademarks, copyrights and other registered IP owned or filed by the acquired company, demonstrating the standard of IP disclosure that sophisticated international acquirers impose even in consumer technology transactions where patents are not the primary value driver. For technology company acquisitions in India, the lesson is that IP due diligence must be calibrated to the actual composition of the target’s value where proprietary algorithms, software platforms and brand identity dominate, the due diligence must examine trade secrets, software copyright, contractor assignment documentation and open-source compliance with equal rigour to patent title verification.
The Natco Pharma v. Bayer compulsory licensing decision of 2012, while not itself an M&A transaction, has become one of the most consequential reference points for pharmaceutical patent due diligence in India. As noted by practitioners at Mondaq in a 2026 analysis of Indian M&A and fundraising, any acquirer of an Indian pharmaceutical company holding product patents must now conduct a specific compulsory licensing risk assessment as a standard component of deal diligence. A patent estate that appears legally robust duly granted, properly registered, commercially exploited may carry material compulsory licensing exposure that must be reflected in deal valuation, if its products are priced in a manner that Indian regulatory and judicial authorities might characterize as inconsistent with the affordability and public availability standards established under Section 84 of the Patents Act.
Regulatory Dimensions – Competition Law and Patent Portfolios
Patent due diligence in M&A transactions must also engage with the intersection of patent law and competition regulation an intersection that has grown significantly more important following the Delhi High Court’s recognition, in Telefonaktiebolaget LM Ericsson v. Competition Commission of India (2016), that the Competition Commission of India has concurrent jurisdiction to scrutinize IP licensing conduct that amounts to abuse of dominance. In transactions involving the acquisition of large patent portfolios particularly in technology sectors where the acquired patents cover standard-essential or foundational technologies the Competition Commission’s merger review process will assess whether the transaction creates or strengthens a dominant position that could be exploited through restrictive licensing practices.
The CCI’s merger review authority under the Competition Act, 2002 applies to transactions meeting the applicable turnover and asset thresholds, and in recent years the CCI has demonstrated increasing willingness to examine the IP dimensions of proposed transactions. Acquirers of patent-heavy businesses must therefore plan for the possibility that merger clearance may require behavioral commitments regarding future licensing conduct particularly in sectors where the acquired patents cover technologies on which competitors depend.
Post-Closing Considerations – Registration, Integration and Warranty Cover
Patent due diligence does not end at closing; it sets the agenda for post-closing IP integration, which is a distinct and often inadequately planned phase of the M&A process. Patents and patent applications that are assigned as part of the transaction must be formally recorded at the Indian Patent Office under Section 68 of the Patents Act. This registration is not automatic and requires the submission of the assignment document, the prescribed form and the applicable fee. Until registration is completed, the assignment is not effective against third parties, leaving the acquirer in the commercially unacceptable position of holding patents it legally owns but cannot enforce against infringers who have no constructive notice of the assignment.
The transfer of licensed patent rights where the target company is a licensee under third-party patents requires verification that each material licence is validly transferred or novated to the acquirer and that any required third-party consents have been obtained. The due diligence process should have identified change-of-control provisions in material licenses; the post-closing integration process must ensure that those provisions have been addressed, either through pre-closing consent or through post-closing novation.
Warranty and Indemnity insurance for Indian M&A deals which provides buyers with direct insurer recourse for breaches of IP representations without requiring litigation against sellers has grown significantly since 2019 and has become a standard risk management tool in mid-to-large cap transactions. The due diligence report’s assessment of IP risks is the foundation on which underwriter’s price and scope the W&I cover. A thorough, well-structured due diligence report that correctly identifies and quantifies IP risks enables more effective W&I coverage; an incomplete or superficial report leaves residual IP risks uninsured and unmitigated.
The Due Diligence Report – From Compliance Catalogue to Decision Tool
The due diligence report is the culminating product of the patent due diligence exercise and its quality determines whether the exercise has served its purpose. A due diligence report that simply catalogues identified risks without quantifying their probability or commercial materiality, without recommending concrete mitigation measures and without expressing a clear view on the IP-related adjustments that the deal price or structure should reflect, is a compliance document rather than a decision tool. The deal team the acquisition committee, the investment committee, the financing banks needs the due diligence report to tell them not merely what the risks are but what they mean for the transaction: what price adjustment, if any, is warranted; what representations, warranties and indemnities should be required; what per-closing remediation should be made a condition of closing; and what post-closing actions are required to secure and integrate the acquired IP estate.
The composition of the due diligence team must reflect the IP composition of the transaction. Pharmaceutical deals demand patent practitioners with pharmacological and chemical expertise capable of assessing the technical and legal strength of drug patents and evaluating Section 3(d) vulnerability. Technology transactions require practitioners familiar with software copyright, open-source licensing obligations and the rapidly developing Indian legal landscape around data and artificial intelligence. Manufacturing and industrial deals require engineers and patent attorneys capable of assessing process patent claims and freedom-to-operate risk in the relevant technical field. General IP counsel alone, without the necessary technical depth, cannot conduct defensible patent due diligence in any of these sectors.
Conclusion
Patent valuation and due diligence in M&A transactions have evolved from a peripheral formality into a central and determinative element of responsible deal practice in India. The legal framework under the Patents Act, 1970, with its distinctive provisions on assignment registration, employee invention ownership, compulsory licensing exposure and Section 3(d) patentability, creates a risk landscape that is uniquely Indian in important respects and that demands India-specific diligence, not merely the transplantation of due diligence templates developed for other jurisdictions. The landmark transactions of the Indian market, from Sun Pharma’s acquisition of Ranbaxy, with its layered regulatory and patent portfolio complexities, to Walmart’s acquisition of Flipkart, with its technology and brand IP dimensions, each confirm, from different angles, that IP risk is quantifiable, transactional and frequently decisive.
As India’s economy continues to grow, its startup ecosystem matures, and cross-border acquisitions of Indian technology, pharmaceutical and industrial companies intensify, the commercial and legal sophistication of patent due diligence practice must keep pace with the rising stakes. The acquirer who invests in rigorous, technically informed and commercially calibrated patent due diligence does not merely manage risk they position themselves to price transactions accurately, structure protections effectively and extract the full value from the intangible assets that increasingly define what they have bought.
References
- The Patents Act, 1970 – https://ipindia.gov.in
- Patents (Amendment) Rules, 2024 – https://ipindia.gov.in
- Competition Act, 2002 – https://cci.gov.in
- Tripathi, A. and Kumar, P. Intellectual Property Due Diligence in Mergers and Acquisitions: A Legal Framework Analysis, SSRN (2026) https://papers.ssrn.com/sol3/papers.cfm?abstract_id=6301938
- Mondaq Intellectual Guardians in the Deal Room: IP Due Diligence in Indian M&A and Fundraising (2026) https://www.mondaq.com/india/maprivate-equity/1803746/intellectual-guardians-in-the-deal-room-ip-due-diligence-in-indian-mergers-and-acquisitions-ma-and-fundraising
- Novartis AG v. Union of India (2013) 6 SCC 1 – https://patenevo.in/novartis-ag-v-union-of-india-others/
- Bayer Corporation v. Natco Pharma Ltd., Controller of Patents (2012); IPAB (2013) – https://patenevo.in/bayer-corporation-v-union-of-india-ors/
- Darius Rutton Kavasmaneck v. Gharda Chemicals Ltd., (2014) SCC Online Bom 1851 – https://indiankanoon.org/doc/135824143/
- Telefonaktiebolaget LM Ericsson v. Competition Commission of India, W.P.(C) 464/2014 – https://patenevo.in/telefonaktiebolaget-lm-ericsson-publ-v-competition-commission-of-india-another/
- Sun Pharmaceutical Industries Ltd v. Ranbaxy Laboratories Ltd., CCI Order, C-2015/05/170 – https://www.casemine.com/judgement/in/5a6575ed4a9326024ad39cd6
- Walmart-Flipkart Share Issuance and Acquisition Agreement (May 9, 2018), SEC Filing – https://www.sec.gov/Archives/edgar/data/104169/000010416918000086/exhibit101shareissuancea.htm
- Ahlawat Associates IP Valuation in India for Startups, M&A and Cross-Border Deals – https://www.ahlawatassociates.com/blog/ip-valuation-india-startups-ma-cross-border-deals
- Lexology Securing the Deal: The Power of IP Due Diligence in M&A Transactions – https://www.lexology.com/library/detail.aspx?g=7b5c94c7-4fd0-4c78-aef9-34e4c7778b79
Compulsory Licensing Copyright Act Copyright Act 1957 copyright case laws Copyright Enforcement Copyright Infringement Copyright Law Copyright Registration Copyright Rules Descriptive Marks India Indian IP Framework Indian Patent Act Indian Patent Law Indian Trademark Law Intellectual Property Law IP Law India Patent Claims Patent Enforcement Patent Infringement Patent law Patent Revocation Patents Act 1970 Section 9 Trade Marks Act Section 29 The Patent Act 1970 Trademark Infringement Trademark Registration Trade Marks Act 1999 Trade Marks Rules 2017 TRIPS Compliance